Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase III study of ferric derisomaltose (NS-32) in iron deficiency anemia associated with gastrointestinal diseases
jRCT2080224507Phase 3Completed
- Sponsor
- Nippon Shinyaku
- Start
- Jan 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of ferric derisomaltose in iron deficiency anemia (IDA) and gastrointestinal bleeding (2 arms), sponsored by Nippon Shinyaku. Started Jan 2019; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)gastrointestinal bleeding
Beyond the preview
Go deeper on jRCT2080224507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224507.